Knopp Biosciences raises $5M, pivots flailing ALS drug to aim new indication

December 12, 2014 - als

December 11, 2014 7:09 pm by | 0 Comments MedCity News

A lot of hopes were pinned on regulating dexpramipexole to provide those with ALS. But it the small proton drug, suspicion to say mitochondrial function, flopped in Biogen Idec’s Phase 3 trials final year: Though fast-tracked in 2009 for a indication, it failed to uncover any statistical efficiency in improving a symptoms or lifespan of patients with Lou Gehrig’s disease.

That said, Pittsburgh startup Knopp Biosciences is still actively study dexpramipexole: It only lifted about $5 million in a new fundraise from 18 investors, and has a go-ahead from a NIH to investigate a devalue in a horde of other diseases – including ALS.

Of course, this is tiny potatoes for a association that lifted $140 million in 2010 – in a days when dexpramipexole was earnest for ALS – though this new appropriation turn shows that investors still have some faith in a molecule’s effifacy.

Here’s Knopp’s pipeline:


The NIH’s National Institute of Allergy and Infectious Diseases is operative with Knopp to control a clinical hearing of dexpramipexole in hypereosinophilic syndrome, or HES, that causes mixed organ damage.

Dexpramipexole is closely associated to pramipexole, a dopamine agonist ordinarily used in treating Parkinson’s illness and nervous legs syndrome underneath trade names Mirapex, Mirapexin and Sifrol.


Copyright 2014 MedCity News. All rights reserved. This element might not be published, broadcast, rewritten or redistributed.

Hear a latest attention news first

Get the daily newsletter or follow us.

Please enter your email below:

Meghana Keshavan

source ⦿

More als ...

› tags: als /